November 3, 2023

Jaisim Shah Chief Executive Officer Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303

Re: Scilex Holding

Company

Registration

Statement on Form S-1

Filed October 20,

2023

File No. 333-275117

Dear Jaisim Shah:

We have conducted a limited review of your registration statement and have the

following comments.

Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe a comment applies to your facts and circumstances

or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you

provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 filed October 20, 2023

Cover Page

In relation to the 13,000,000 shares of common stock issuable upon exercise of the warrants issued to Oramed Pharmaceuticals Inc. in the September 21, 2023, private placement, please tell us your basis for registering the offering of these shares on a primary basis. In this regard, we note that these shares and warrants were issued pursuant to the exemptions provided in Section 4(a)(2) of the Securities Act, and it appears that the warrants may be exercisable within one year. Please consider the rationale set out in Securities Act Sections C&DI Questions 139.08, 239.15, and 103.04.

Recent Developments

September 2023 Preliminary Unaudited Financial Results, page 4

We note your disclosure of preliminary sales amounts for the period ending September 30, 2023. It appears this disclosure in isolation may provide an incomplete picture of your Jaisim Shah Scilex Holding Company

November 3, 2023

Page 2

financial results. Please provide context for the preliminary results by also disclosing net

loss estimates or other line items for the same period.

We remind you that the company and its management are responsible for the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration

statement.

Please contact Jimmy McNamara at 202-551-7349 or Jason Drory at 202-551-8342 with any other questions.

FirstName LastNameJaisim Shah

Corporation Finance Comapany NameScilex Holding Company

Sciences

November 3, 2023 Page 2 cc: Elizabeth Razzano
FirstName LastName

Sincerely,

Division of

Office of Life